Management of Treatment-Experienced HIV-Infected Patients
Summary
- Determination must be made as to likelihood that at least 2—if not 3—fully active drugs can be combined in next regimen
- Unless a boosted PI is likely to be fully active, the use of < 2 fully active drugs is associated with high risk of selecting for resistance to any new drugs and further limiting future treatment options
- Evidence-based management standards argue for inclusion of NRTIs and ritonavir-boosted PIs in new regimens for treatment-experienced patients
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content